T. Rowe Price Associates’s Parabilis Medicines PBLS Stock Holding History
Bought
Maintained
Sold
Other funds holding PBLS
SL
T. Rowe Price Associates's PBLS Position: Q3 2026 in Review
T. Rowe Price Associates increased its Parabilis Medicines (PBLS) stake by 2% in Q3 2026, buying an estimated $516K and bringing the position to 766,727 shares worth $24.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1049.
T. Rowe Price Associates first reported a position in PBLS in Q2 2026 and has held it in 2 quarters since. 127 funds tracked by Wall St. Rank hold PBLS as of Q3 2026.
- T. Rowe Price Associates held 766,727 shares of Parabilis Medicines worth $24.8M as of Q3 2026.
- T. Rowe Price Associates bought 14,780 Parabilis Medicines shares in Q3 2026, an estimated $516K.
- Parabilis Medicines made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q3 2026, its #1049 holding.
- T. Rowe Price Associates first reported a position in Parabilis Medicines in Q2 2026 and has held it in 2 quarters since.
- 127 funds tracked by Wall St. Rank held Parabilis Medicines as of Q3 2026.
Based on T. Rowe Price Associates's 13F filing for Q3 2026, filed 16 Nov 2026.